Solid has a diversified pipeline across neuromuscular and cardiac diseases with indications we believe are characterized by high unmet need, clear mechanistic rationale, and significant market opportunities
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
Neuromuscular
SGT-003 Duchenne
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
SGT-212 Friedreich's ataxia
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
Cardiac
SGT-501 RYR2-Mediated CPVT
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
SGT-501 CASQ2-Mediated CPVT
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
SGT-601 TNNT2 DCM
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
SGT-401 BAG3-Mediated DCM
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
SGT-701 RBM20 DCM
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
Mayo Clinic Collaboration Six Undisclosed Targets
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
Platform
Capsid Library
Research/ Discovery
Preclinical
IND Submission
Phase I/II
Phase III
As we move forward, we expect to see a diversified pipeline, including emerging technologies that will be evaluated for their potential to target underlying diseases and bring groundbreaking genetic therapies to more patients.
Following is the jquery code that sets the body class to the page without a photo hero